Medicare’s GLP-1 Bridge program covers weight-loss drugs for beneficiaries with a body mass index of 35 or higher, and for some beneficiaries with a lower BMI who also carry a specific weight-related health risk, such as uncontrolled high blood pressure or a prior heart attack. The Centers for Medicare & Medicaid Services built the eligibility rules around three separate BMI tiers, each pairing a lower threshold with a narrower list of qualifying conditions. The program itself is a stopgap: CMS created and then extended it after a larger, permanent coverage plan for the same drugs stalled inside Medicare’s own Part D plans.
The three BMI tiers and the conditions that lower the bar
A beneficiary with a BMI of 35 or higher qualifies for the Bridge without any additional diagnosis. That threshold alone covers the broadest slice of the BMI-based pathway; anyone below it needs a specific medical risk factor layered on top of a lower BMI in order to enroll.
A BMI between 30 and 34.9 qualifies only alongside at least one of three listed conditions, according to Medicare’s own eligibility page for the program: diastolic heart failure, also called heart failure with preserved ejection fraction; uncontrolled high blood pressure; or chronic kidney disease at stage 3a or higher. A BMI between 27 and 29.9 requires a different set of risk factors instead — prediabetes, a previous heart attack or stroke, or peripheral artery disease in the legs or arms with symptoms — narrowing the list of qualifying conditions as the BMI threshold itself drops.
Three medications are covered under those tiers, per the same Medicare eligibility page: Wegovy, available as an injection or a tablet; Zepbound, but only in its KwikPen device, not the single-dose vials or pens; and Foundayo, a tablet. A beneficiary already diagnosed with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease cannot enroll even if their BMI and other risk factors otherwise qualify, and a prescriber must certify that the drug is paired with a lifestyle program focused on diet and exercise.
Enrollment also requires that a beneficiary be at least 18 years old, carry Medicare Part D drug coverage, and not already be receiving a GLP-1 drug through their existing Part D benefit; someone already filling a GLP-1 prescription through standard Part D coverage is not eligible to move into the Bridge’s copay instead.
What the BMI tiers do not settle: Qualifying under the 27, 30 or 35 BMI thresholds only opens the door to the program’s reduced copay; it does not say whether a beneficiary’s own Part D plan already covers the drug, what happens to the prescription once the demonstration ends in December 2027, or how to appeal a plan’s denial. See the prior-authorization appeal steps in The Medicare Cost & Coverage Protection Kit.
A stopgap that exists because a bigger Medicare model stalled
The Bridge exists because a larger, permanent coverage plan for the same drugs did not survive contact with Medicare’s own drug plans. The Center for Medicare and Medicaid Innovation had built the BALANCE Model to negotiate broader GLP-1 coverage across both Medicaid and Medicare Part D, but CMS required 80% of Part D plan sponsors to opt in before the Part D side could proceed, and that threshold was not met, with major plan sponsors reportedly reluctant to take on the projected cost.
CMS announced in April 2026 that it would not move forward with BALANCE inside Medicare Part D for 2027, and used that decision to extend the GLP-1 Bridge’s end date from its original December 31, 2026 cutoff out to December 31, 2027, keeping the reduced copay in place while the agency collects more utilization data. BALANCE itself continues on a separate track in Medicaid, where it launched in May 2026 and is scheduled to run through December 2031, unrelated to the Medicare eligibility rules that govern the Bridge.
CMS Administrator Dr. Mehmet Oz described the underlying problem when the agency first detailed the program’s copay structure, saying these treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost, in a May 6 announcement. Chris Klomp, the Medicare director at the Department of Health and Human Services, added that the drugs can be life-changing for patients managing obesity and related conditions, framing the Bridge as an interim fix for an access problem the permanent model was meant to solve.
What the reduced copay actually buys, and what it does not
The program’s copay does not count toward a beneficiary’s true out-of-pocket costs, the running total that normally triggers Medicare’s catastrophic coverage phase, and the standard Part D deductible does not apply to it either. Beneficiaries who qualify for the Part D Low-Income Subsidy cannot use it to lower the Bridge’s copay any further, because the demonstration operates outside the standard Part D benefit structure rather than inside it.
Manufacturers supply the covered drugs to the program at a net price of $245 for a 30-day supply, according to the same KFF analysis of the arrangement, well below the roughly $1,000 monthly list price GLP-1 drugs have carried for patients paying without insurance. That gap between the manufacturer’s negotiated price and the beneficiary’s own charge is what the Bridge is actually subsidizing, and the subsidy lasts only through the end of 2027 unless CMS builds a longer-term replacement before the BALANCE Model’s Part D component gets another chance.
The BMI rule opens a door; the plan decides what is on the other side
Meeting one of the program’s BMI-and-risk-factor combinations qualifies a beneficiary for the demonstration itself, but it does not guarantee a specific Part D plan will process the claim smoothly, or that the prescription survives the program’s scheduled end in December 2027 without a new coverage decision.
The Medicare Cost & Coverage Protection Kit includes the prior-authorization appeal steps for a denied claim and a medication-and-cost tracker for recording each fill, the refill date and what the plan actually charged.
Read the appeal steps in The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
